{"brief_title": "Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture", "brief_summary": "The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive vitamin D and calcium.", "condition": ["Osteoporosis", "Hip Fracture"], "intervention_type": ["Drug"], "intervention_name": ["Zoledronic Acid"], "criteria": "Inclusion Criteria: - Male or female ages 50 years or older - Must have a recent hip fracture repair in the past 90 days - Must be able to walk with or without assistive device (for example, using a walker) prior to the hip fracture Exclusion Criteria: - Current bisphosphonate users such as aredia (pamidronate), didronel (etidronate), fosamax (alendronate), actonel (residronate), skelid (tiludronate) Other protocol-defined inclusion/exclusion criteria may apply.", "gender": "All", "minimum_age": "50 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "orthopedic", "mesh_term": ["Fractures, Bone", "Osteoporosis", "Hip Fractures", "Osteoporotic Fractures", "Zoledronic acid", "Diphosphonates"], "id": "NCT00046254"}